Wednesday, June 21, 2023
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.
Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Patient Enrollment Updated. MAIA Biotechnology announced that the THIO-101 trial has enrolled 29 patients (out of 57 total patients) in Part B of the trial. Enrollment has been increasing since the recent opening of 13 new clinical trial sites in Eastern Europe. This stage of the trial is evaluating the safety, tolerability, and dosing for the Part C efficacy stage. The trial is on schedule to announce data in 3Q/4Q23.
MAIA Continues To Make Clinical Progress. The THIO-101 trial is testing THIO, a nucleoside analogue targeted at the telomeres of cancer cells. When THIO is taken up by the reproducing DNA, it stops the replication and leads to cell death, then starts an inflammatory response in the tumor. Preclinical models have demonstrated efficacy in several tumor types.
Get the Full Report
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.